Stockscreener 앱 받기
15.45
3.83%
0.57
시간 외 거래:
15.62
0.17
+1.10%
Dyne Therapeutics Inc 주식(DYN)의 최신 뉴스
Dyne Therapeutics (DYN) to Showcase Key Developments at 2026 MDA Conference - GuruFocus
Dyne Therapeutics to Showcase Positive Results from DELIVER Trial and Phase 3 Trial Design at 2026 MDA Clinical & Scientific Conference - Quiver Quantitative
Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference - The Manila Times
New heart-lung data in rare muscle diseases: inside Dyne’s 2026 trial push - Stock Titan
Aberdeen Group plc Purchases 72,770 Shares of Dyne Therapeutics, Inc. $DYN - MarketBeat
Aug PostEarnings: Is Dyne Therapeutics Inc a turnaround storyBreakout Watch & Entry Point Confirmation Signals - baoquankhu1.vn
Bullish Analyst Opinion on Dyne (DYNE) Follows Rare Disease Drug Progress in Japan - Finviz
VIX Spike: What is Dyne Therapeutics Incs 5 year growth outlookIPO Watch & Weekly Sector Rotation Insights - baoquankhu1.vn
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Exploring a 151% Upside Potential in Biotech - DirectorsTalk Interviews
Weekly Trades: Can Dyne Therapeutics Inc disrupt its industry2025 Bull vs Bear & Weekly High Return Forecasts - baoquankhu1.vn
Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry - Finviz
Dyne Therapeutics announces $300M proposed public offering - MSN
Can Dyne Therapeutics Inc. disrupt its industryWeekly Risk Summary & Daily Profit Focused Stock Screening - mfd.ru
Earnings Risk: Is Dyne Therapeutics Inc gaining market shareJuly 2025 Movers & Verified Momentum Stock Watchlist - baoquankhu1.vn
What is Dyne Therapeutics Inc. s 5 year growth outlookChart Signals & Verified Swing Trading Watchlists - mfd.ru
Facioscapulohumeral Muscular Dystrophy Market: High-Growth Opportunities for Investors to 2034 – DelveInsight | Dyne Therapeutics, miRecule, Avidity Biosciences, aTyr Pharma, Fulcrum Therapeutics - Barchart.com
Facioscapulohumeral Muscular Dystrophy Market: High-Growth - openPR.com
(DYN) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Will Dyne Therapeutics Inc. benefit from current market trendsLong Setup & Daily Technical Forecast Reports - mfd.ru
Candriam S.C.A. Has $10.55 Million Stock Position in Dyne Therapeutics, Inc. $DYN - MarketBeat
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Unveiling A 130% Potential Upside - DirectorsTalk Interviews
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: Key - openPR.com
Facioscapulohumeral Muscular Dystrophy Pipeline 2025: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Fulcrum Therapeutics, Dyne Therapeutics, GSK, Roche, Facio Therapies - Barchart.com
History Review: Is now the right time to enter Dyne Therapeutics IncJuly 2025 Gainers & Long-Term Capital Growth Strategies - baoquankhu1.vn
Dyne Therapeutics Approaches Key Regulatory Milestones in 2026 - AD HOC NEWS
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Biotech Contender with a 108% Upside Potential - DirectorsTalk Interviews
Dyne Therapeutics, Inc. (NASDAQ:DYN) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
(DYN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
Pullback Watch: Can Dyne Therapeutics Inc scale operations efficientlyPortfolio Risk Summary & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Published on: 2026-01-28 16:56:14 - baoquankhu1.vn
Dyne Therapeutics, Inc. (DYN) Stock Analysis: Unveiling a 117% Potential Upside in Biotechnology - DirectorsTalk Interviews
Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? - The Globe and Mail
Dyne Therapeutics: 2026 Catalysts Point To Further Upside (NASDAQ:DYN) - Seeking Alpha
Dyne Therapeutics (DYN) Is Up 7.8% After Japan Grants Orphan Status To DM1 Drug Candidate - Sahm
FY2025 Earnings Forecast for DYN Issued By Lifesci Capital - MarketBeat
How Does Japan’s Orphan Nod Shape Dyne Therapeutics’ (DYN) Global Rare-Disease Strategy? - Yahoo Finance
(DYN) Risk Channels and Responsive Allocation - Stock Traders Daily
LifeSci Capital Maintains Dyne Therapeutics(DYN.US) With Buy Rating, Maintains Target Price $44 - 富途资讯
CEO Change: What is Dyne Therapeutics Incs 5 year growth outlookQuarterly Portfolio Report & AI Enhanced Trading Alerts - baoquankhu1.vn
Dyne Therapeutics, Inc. (DYN) Stock Analysis: A Biotech Powerhouse with 134% Upside Potential - DirectorsTalk Interviews
JPMorgan Chase & Co. Lowers Dyne Therapeutics (NASDAQ:DYN) Price Target to $16.00 - MarketBeat
JP Morgan Updates Dyne Therapeutics (DYN) with a Neutral Rating - GuruFocus
Dyne Therapeutics (DYN) Gains Orphan Drug Status in Japan for DM - GuruFocus
Dyne Therapeutics Receives Orphan Drug Designation in Japan - GlobeNewswire
Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 - Sahm
Campbell & CO Investment Adviser LLC Purchases Shares of 64,517 Dyne Therapeutics, Inc. $DYN - MarketBeat
JP Morgan Updates Dyne Therapeutics (DYN) with a Neutral Rating | DYN Stock News - GuruFocus
Can Dyne Therapeutics Inc. scale operations efficientlyMarket Rally & Stepwise Trade Signal Implementation - bollywoodhelpline.com
Why Dyne Therapeutics Stock Was Crushing it This Week - AOL.com
Jobs Data: Is Dyne Therapeutics Inc a turnaround storyWeekly Profit Report & Free Accurate Trade Setup Notifications - baoquankhu1.vn
Oppenheimer Upgrades Dyne Therapeutics (DYN) to Outperform, Rais - GuruFocus
14 Best Booming Stocks to Buy Right Now - Insider Monkey
Dyne Therapeutics (NASDAQ:DYN) Trading Down 4.9%Here's What Happened - MarketBeat
Is Dyne Therapeutics' (DYN) Late-Stage DMD Progress Redefining Its Rare Disease Investment Story? - simplywall.st
Analysts project 120% upside to Dyne Therapeutics, Inc. (DYN) - MSN
Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN) - Insider Monkey
2.25%
0.47%
자본화:
|
볼륨(24시간):